In the context of inflammatory arthritis, FPR2 activation by ANXA1 (Kao et al., 2014) or the resolvins RvD1 (Norling et al., 2016) and resolvin 3 (RvD3; Arnardottir et al., 2016) leads to clinical remission and reduces disease severity in murine arthritis, as well as affording bone (Kao et al., 2014) and cartilage (Norling et al., 2016) protection. Here, FPR2 is linked to arthritic joint disease.